Oncotarget

Research Papers:

A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct

Cory A. Ocasio _, Mohan B. Rajasekaran, Sarah Walker, Darren Le Grand, John Spencer, Frances M.G. Pearl, Simon E. Ward, Velibor Savic, Laurence H. Pearl, Helfrid Hochegger and Antony W. Oliver

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:71182-71197. https://doi.org/10.18632/oncotarget.11511

Metrics: PDF 1678 views  |   HTML 1768 views  |   ?  


Abstract

Cory A. Ocasio1,3,*, Mohan B. Rajasekaran2,*, Sarah Walker3, Darren Le Grand3, John Spencer4, Frances M.G. Pearl4, Simon E. Ward3, Velibor Savic1,5, Laurence H. Pearl2, Helfrid Hochegger1 and Antony W. Oliver2

1 Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, UK

2 Cancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, UK

3 Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, UK

4 School of Life Sciences, University of Sussex, Falmer, Brighton, UK

5 Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK

* The authors wish it to be known, that in their opinion, the first 2 authors should be regarded as joint first authors

Correspondence to:

Cory A. Ocasio, email:

Helfrid Hochegger, email:

Antony W. Oliver, email:

Keywords: kinase, inhibitor, Greatwall, ENSA, cancer

Received: July 20, 2016 Accepted: August 02, 2016 Published: August 22, 2016

Abstract

MASTL (microtubule-associated serine/threonine kinase-like), more commonly known as Greatwall (GWL), has been proposed as a novel cancer therapy target. GWL plays a crucial role in mitotic progression, via its known substrates ENSA/ARPP19, which when phosphorylated inactivate PP2A/B55 phosphatase. When over-expressed in breast cancer, GWL induces oncogenic properties such as transformation and invasiveness. Conversely, down-regulation of GWL selectively sensitises tumour cells to chemotherapy. Here we describe the first structure of the GWL minimal kinase domain and development of a small-molecule inhibitor GKI-1 (Greatwall Kinase Inhibitor-1). In vitro, GKI-1 inhibits full-length human GWL, and shows cellular efficacy. Treatment of HeLa cells with GKI-1 reduces ENSA/ARPP19 phosphorylation levels, such that they are comparable to those obtained by siRNA depletion of GWL; resulting in a decrease in mitotic events, mitotic arrest/cell death and cytokinesis failure. Furthermore, GKI-1 will be a useful starting point for the development of more potent and selective GWL inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11511